- Geron ( NASDAQ: GERN ) is trading ~6% higher after the company posted narrower-than-expected quarterly loss.
- The company's Q2 GAAP EPS of -$0.07 beat estimates by $0.02.
- Total operating expenses for the three months were $28M, compared to $29M, a year earlier.
- Research and development expenses were $20.6M, compared to $21.9M, primarily reflects the net result of decreased manufacturing costs due to the timing of imetelstat manufacturing batches.
- Revenue fell 30% Y/Y to $0.07M, and missed by $0.04M.
For further details see:
Geron rises on narrower-than-expected Q2 loss